Pearl River Capital’s Tvardi Therapeutics TVRD Stock Holding History

Pearl River Capital’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-22	Closed	-$10K	–	842
2018 Q4	$10K	Buy	+22	New	+$14.2K	0.05%	571

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Pearl River Capital's TVRD Position: Q1 2019 in Review

Pearl River Capital sold out of Tvardi Therapeutics (TVRD) in Q1 2019, closing a stake of 22 shares — an estimated $10K sold.

Pearl River Capital first reported a position in TVRD in Q4 2018 and held it in 1 quarter. The position peaked at $10K in Q4 2018. 135 funds tracked by Wall St. Rank hold TVRD as of Q1 2019.

Pearl River Capital reported no remaining Tvardi Therapeutics position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 22 Tvardi Therapeutics shares in Q1 2019, an estimated $10K.
Pearl River Capital first reported a position in Tvardi Therapeutics in Q4 2018 and held it in 1 quarter.
Pearl River Capital's Tvardi Therapeutics position peaked at $10K in Q4 2018.
135 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.